Rheumatoid Arthritis Clinical Trials in New York

Showing 2821-2840 of 4,168 trials

TERMINATEDNA< 1 mile

ReNu™ Marrow Stimulation Augmentation

NCT03036878

To evaluate the use of ReNu™ allograft for the augmentation of marrow stimulation for osteochondral lesions

Osteochondral Defect

NuTech Medical, Inc1 participantsStarted Feb 2017

Indianapolis, Indiana, United States • New York, New York, United States

Approved For Marketing< 1 mile

Zenith® TX2® Low Profile TAA Endovascular Graft

NCT02471781

The Zenith TX2 Low Profile TAA Endovascular Graft extended study is to collect confirmatory safety and effectiveness data. The Zenith TX2 Low Profile TAA Endovascular Graft is indicated for the treatment of patients with a descending thoracic aortic aneurysm or penetrating ulcer and has an anatomy suitable for repair.

Aortic AneurysmPenetrating UlcerVascular Disease

Cook Group Incorporated

Tampa, Florida, United States • Atlanta, Georgia, United States • Indianapolis, Indiana, United States +12 more locations

TERMINATEDPhase 3< 1 mile

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

NCT02556203

To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing death or first thromboembolic events (DTE). To assess the primary bleeding events (PBE) of the rivaroxaban-based strategy compared to an antiplatelet-based strategy, following TAVR.

Transcatheter Aortic Valve Replacement

Bayer1,653 participantsStarted Dec 2015

Los Angeles, California, United States • Washington D.C., District of Columbia, United States • Clearwater, Florida, United States +137 more locations

ReNu™ Marrow Stimulation Augmentation

Zenith® TX2® Low Profile TAA Endovascular Graft

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Rheumatoid Arthritis Trials in Other Cities

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Effectiveness of Propranolol For Treating People With Post-Traumatic Stress Disorder

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers

EverFlex Post Approval Study

A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

Answer ALS: Individualized Initiative for ALS Discovery

Esteem Totally Implantable Hearing System

Farber Disease Natural History Study

Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

Other Conditions in New York